# Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Study · id `cardio:ct-nct06290349` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06290349](<https://clinicaltrials.gov/study/NCT06290349>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06290349

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 174 participants.

## Technical summary

Registry record NCT06290349. Randomized; double masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2025-09-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 174 participants (enrolled count; ClinicalTrials.gov record NCT06290349, source copy `cardio:ctgov-nct06290349-2025-11-19`, retrieved 2026-10-26)
- Started: 2024-04-01 (actual) (ClinicalTrials.gov record NCT06290349, source copy `cardio:ctgov-nct06290349-2025-11-19`, retrieved 2026-10-26)
- Primary completion: 2025-09-05 (actual) (ClinicalTrials.gov record NCT06290349, source copy `cardio:ctgov-nct06290349-2025-11-19`, retrieved 2026-10-26)
- Completion: 2026-03-31 (anticipated) (ClinicalTrials.gov record NCT06290349, source copy `cardio:ctgov-nct06290349-2025-11-19`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06290349, source copy `cardio:ctgov-nct06290349-2025-11-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06290349-2025-11-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
- Condition: Type 2 Diabetes
- Intervention (Drug): DA5221-T1
- Intervention (Drug): DA5221-T2
- Intervention (Drug): Placebo
- Intervention (Drug): DA5221-B1
- Intervention (Drug): DA5221-B2
- Lead sponsor: Dong-A ST Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Dong-A ST Co., Ltd. (`cardio:org-dong-a-st-co-ltd`)

## Provenance

Content hash: 0ba19b0143d2a57d821ebfc519f4461182a4efc43a275bae7a6f61d00fd6acf9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
